OMass Therapeutics is a biotechnology company developing small molecule therapeutics against highly validated target ecosystems. Its proprietary OdyssION™ drug discovery platform combines next-generation native mass spectrometry, novel biochemistry techniques and custom chemistry to interrogate drug targets within their native ecosystems, providing cell-system fidelity with cell-free precision.
OMass’ lead program, OMS1620, is a best-in-class MC2 (melanocortin-2) receptor antagonist for congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing’s syndrome, designed to maintain efficacy in the presence of elevated ACTH levels. OMass is also advancing a broader preclinical pipeline including an SLC15A4 inhibitor for lupus and other indications related to interferon overproduction and pathogenic B-cell activation.
Headquartered in Oxford, UK, OMass was founded as a spin-out from Professor Dame Carol Robinson’s lab at the University of Oxford to translate pioneering native mass spectrometry research into novel small molecule therapeutics against historically challenging targets. The Company is backed by a top-tier international investor syndicate.
